Comparative PB engraftment analysis in IUT and postnatal BMT recipients. BALB/c-SCID recipients were treated via IUT or postnatal BMT, with the indicated B6 BM cell dose shown in parentheses. Recipients received TCD or NTCD BM as indicated. Additional control groups consisted of BALB/c-SCID recipients of BALB/c BM (congenic [cong.]) and BALB/c recipients were treated with TBI and received B6 TCD BM. Where indicated, controls are non-BMT B6 mice. The mean proportion of PB-expressing H2^b (A), CD4 (C), CD8 (D), and B220 (B cells) (E) antigens are listed on the y-axis. The mean percentage of donor myeloid engraftment (B) was calculated by dividing the percentage of H2b⁺ Mac1⁺ cell population by the total Mac1⁺ cells. A composite graph (F) of the relative mean proportion of donor CD4⁺, CD8⁺, B220⁺, Mac1⁺, and host Mac1⁺ cells in individual mice in each group is shown. The number of recipients studied (no.) in each group is listed at the bottom of (F). Symbols for (F): (▪) CD4; (▨) CD8; (□) B220; (▧) H2b Mac1; (▥) H2d Mac1. One standard error of the mean values ranged 0% to 4% for all values shown, except for a value of 9% for H2^b expression in SCID TCD25 recipients. *Significant differences between IUT TCD recipients and other groups. For the assessment of the proportion of PB expressing donor lymphoid markers, the (#) indicates significant differences between the indicated groups and the non-BMT B6 control mice.